Article

85 views

In our ongoing special series ‘BioRise’ we interviewed Mr. Dushyant Singh Baghel, Managing Director & CEO, Nucleome Informatics, India and tried to explore his six-year-old venture, his inspirations and also got to know about his perspectives and advice for bio-entrepreneurship in India.

In our ongoing special series ‘BioRise’ we interviewed Mr. Dushyant Singh Baghel, Managing Director & CEO, Nucleome Informatics, India and tried to explore his six-year-old venture, his inspirations and also got to know about his perspectives and advice for bio-entrepreneurship in India.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in HOW THEY DID IT


HOW THEY DID IT

Interview: Genomics Services to Lead Indian Biotech Industry

In our ongoing special series ‘BioRise’ we interviewed Mr. Dushyant Singh Baghel, Managing Director & CEO, Nucleome Informatics, India and tried to explore his six-year-old venture, his inspirations and also got to know about his perspectives and advice for bio-entrepreneurship in India.

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Healthcare in India is showing a gradual progress and there is an abundance of opportunity to create an evolving business by tackling the major challenges of the mass population. Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our observations of the current Indian market, its behavior, challenges, and opportunities.

MARKET INSIGHTS

9 Most Valuable Drugs Under Development (2018)

The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These drugs are forecasted to be the future blockbuster. With $10,199 million Net Present Value, Aducanumab, the Ant-Alzheimer's investigational drug of Biogen is ranked as the topmost valued upcoming drug under development. Total Word Counts of the article: 782. Continue reading..

Leave a reply